

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***

March 9, 2023

**QUESTIONS**

---

**BLA 761121/S-008**

**POLIVY (polatuzumab vedotin-piiq)**

**Applicant: Genentech, Inc.**

**PROPOSED INDICATION:**

- in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
- 

1. **DISCUSSION:** Discuss the benefit-risk profile of polatuzumab vedotin-piiq in combination with R-CHP for the proposed patient population with large B-cell lymphoma (LBCL), including patients with DLBCL not otherwise specified (NOS), considering the results of the POLARIX trial.
2. **DISCUSSION:** Based on the results of the POLARIX trial, specifically the overall survival results, discuss whether additional follow-up data from POLARIX should be required to inform the benefit-risk of polatuzumab vedotin-piiq in patients with LBCL in the frontline setting.
3. **VOTE:** Given the results of the POLARIX trial, does polatuzumab vedotin-piiq have a favorable benefit-risk profile in patients with previously untreated LBCL, including DLBCL NOS?